NEW YORK, April 14, 2020 /PRNewswire/ -- AIkido Pharma
Incorporated (Nasdaq: AIKI) today announced that it has secured an
exclusive world-wide license for a broad spectrum antiviral drug
platform. The licensed technology is a broadly acting
pan-viral inhibitory compound with efficacy against multiple viral
pathogens. The technology works to inhibit replication of multiple
viruses including Influenza virus, SARS-COV (coronavirus),
MERS-COV, Ebolavirus and Marburg virus.
Anthony Hayes, CEO of AIkido
stated, "This license is a follow up to our March 6, 2020 press release 'Treatment for
Coronavirus Optioned by Spherix.' We continue to vet the technology
we optioned, but this antiviral drug platform technology we've
licensed is broader with more potential applicability, while also
coming from the same lead inventors and institution. We are always
seeking to acquire the best technology to drive shareholder value.
We will continue to investigate the technology covered by our
option and we will be providing additional information about this
antiviral platform shortly. Working to develop technology to help
with the current pandemic, as well as other possible viruses that
may impact us in the future, is our goal for this technology."
About AIkido
AIkido was initially formed in 1967 and
is a biotechnology company with a diverse portfolio of
small-molecule anti-cancer therapeutics. The Company's
platform consists of patented technology from leading universities
and researchers and we are currently in the process of developing
an innovative therapeutic drug platform through strong partnerships
with world renowned educational institutions, including The
University of Texas at Austin and
Wake Forest University. Our diverse
pipeline of therapeutics includes therapies for pancreatic cancer,
acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL). In addition, we are constantly seeking to grow our pipeline
to treat unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the SEC,
not limited to Risk Factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contact:
|
|
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
AIkido:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@AIkido.com
|
|
www.AIkido.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-executes-exclusive-world-wide-license-to-broad-spectrum-antiviral-drug-platform-includes-coronavirus-301039998.html
SOURCE AIkido Pharma Inc.